US equities
|
MU
$903.70
▲+0.00%
META
$630.56
▲+0.00%
TSLA
$391.62
▲+0.00%
SKHY
$142.62
▲+0.00%
SPCX
$146.90
▲+0.00%
NVDA
$216.00
▲+0.00%
SNDK
$1,255.58
▲+0.00%
INTC
$90.47
▲+0.00%
MU
$903.70
▲+0.00%
META
$630.56
▲+0.00%
TSLA
$391.62
▲+0.00%
SKHY
$142.62
▲+0.00%
SPCX
$146.90
▲+0.00%
NVDA
$216.00
▲+0.00%
SNDK
$1,255.58
▲+0.00%
INTC
$90.47
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Aileron Therapeutics, Inc. - Common Stock
(NQ:
ALRN
)
2.110
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aileron Therapeutics, Inc. - Common Stock
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 15, 2024
From
Aileron Therapeutics, Inc.
Via
GlobeNewswire
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
May 06, 2024
From
Aileron Therapeutics, Inc.
Via
GlobeNewswire
BioMedNewsBreaks — Aileron Therapeutics Inc. (NASDAQ: ALRN) Closes Underwritten Registered Direct Offering
May 06, 2024
Via
Investor Brand Network
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
May 03, 2024
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering
From
Aileron Therapeutics, Inc.
Via
GlobeNewswire
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
May 01, 2024
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering
From
Aileron Therapeutics, Inc.
Via
GlobeNewswire
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
May 01, 2024
From
Aileron Therapeutics, Inc.
Via
GlobeNewswire
Aileron Therapeutics Inc. (NASDAQ: ALRN) Leading the Way in Thursday Trading Based on Percentage Gain
April 18, 2024
Via
Investor Brand Network
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 15, 2024
From
Aileron Therapeutics, Inc.
Via
GlobeNewswire
Aileron Therapeutics Announces CEO Transition
March 12, 2024
From
Aileron Therapeutics, Inc.
Via
GlobeNewswire
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
February 15, 2024
Topline results from Phase 1b study of LTI-03, Aileron’s novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024
From
Aileron Therapeutics, Inc.
Via
GlobeNewswire
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
February 01, 2024
Panel discussion will highlight LTI-03, Aileron’s novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis
From
Aileron Therapeutics, Inc.
Via
GlobeNewswire
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
February 21, 2023
From
Aileron Therapeutics, Inc.
Via
GlobeNewswire
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements
November 30, 2022
From
Aileron Therapeutics, Inc.
Via
GlobeNewswire
Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
November 10, 2022
Common Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022
From
Aileron Therapeutics, Inc.
Via
GlobeNewswire
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
November 01, 2022
From
Aileron Therapeutics, Inc.
Via
GlobeNewswire
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference
October 26, 2022
From
Aileron Therapeutics, Inc.
Via
GlobeNewswire
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022
September 30, 2022
From
Aileron Therapeutics, Inc.
Via
GlobeNewswire
